Globus Medical to acquire Nevro for $5.85 per share in all-cash deal
Globus Medical agreed to acquire Nevro Corp. in an all-cash transaction valued at approximately $250 million in total equity value, subject to Nevro shareholder approval, regulatory clearance and other closing conditions. Globus Medical said that after the deal closes it expects higher 2025 net sales but lower non-GAAP earnings per share than its stand-alone guidance.
Key points
- Nevro shareholders will receive $5.85 per share in cash, a 17% premium to Nevro's February 5, 2025 closing price.
- Globus Medical expects the deal to close late in the second quarter of 2025 and anticipates the Nevro acquisition to be accretive to earnings in the second year of operation.
- Post-deal 2025 guidance: net sales of $2.80 billion to $2.90 billion (versus stand-alone $2.66 billion to $2.69 billion) and non-GAAP EPS of $3.10 to $3.40 (versus stand-alone $3.40 to $3.50).
- Termination fees: Nevro would pay $15 million or $10 million in certain circumstances, including a failed stockholder vote; Globus Medical would pay $15 million in certain circumstances.
The filing
Written by AI on Nov 8, 2026, 12:56 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on February 06, 2025.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.